ATE442588T1 - Testverfahren zur identifizierung eines kandidatenarzneistoffs - Google Patents

Testverfahren zur identifizierung eines kandidatenarzneistoffs

Info

Publication number
ATE442588T1
ATE442588T1 AT05728425T AT05728425T ATE442588T1 AT E442588 T1 ATE442588 T1 AT E442588T1 AT 05728425 T AT05728425 T AT 05728425T AT 05728425 T AT05728425 T AT 05728425T AT E442588 T1 ATE442588 T1 AT E442588T1
Authority
AT
Austria
Prior art keywords
soluble
identifying
oligopeptide
polypeptide
protein
Prior art date
Application number
AT05728425T
Other languages
English (en)
Inventor
Naoyuki Sato
Masayasu Okochi
Yoshiaki Taniyama
Toshio Ogihara
Ryuichi Morishita
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Application granted granted Critical
Publication of ATE442588T1 publication Critical patent/ATE442588T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05728425T 2004-03-31 2005-03-30 Testverfahren zur identifizierung eines kandidatenarzneistoffs ATE442588T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004107746 2004-03-31
PCT/JP2005/006728 WO2005095958A1 (ja) 2004-03-31 2005-03-30 薬剤候補を同定するためのアッセイ法

Publications (1)

Publication Number Publication Date
ATE442588T1 true ATE442588T1 (de) 2009-09-15

Family

ID=35063906

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05728425T ATE442588T1 (de) 2004-03-31 2005-03-30 Testverfahren zur identifizierung eines kandidatenarzneistoffs

Country Status (6)

Country Link
US (1) US20090087916A1 (de)
EP (1) EP1739425B1 (de)
JP (1) JPWO2005095958A1 (de)
AT (1) ATE442588T1 (de)
DE (1) DE602005016537D1 (de)
WO (1) WO2005095958A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2667002T3 (es) * 2006-03-29 2018-05-09 Wista Laboratories Ltd. Inhibidores de la agregación de proteínas
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
US8809617B2 (en) * 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
CN114106141A (zh) * 2021-12-13 2022-03-01 中国科学院深圳先进技术研究院 一种β-淀粉样蛋白聚合物的制备方法及其产品和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334337D1 (de) 1992-10-26 2010-08-26 Elan Pharm Inc Verfahren zur Identifizierung von Hemmstoffverbindungen der Freisetzung von Beta-Amyloidpeptid (BAP)
JP2002522747A (ja) * 1998-04-14 2002-07-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 微小管脱重合インヒビターを検出するためのアッセイ
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
JP2002536963A (ja) * 1998-12-22 2002-11-05 ミリアド・ジェネティックス・インコーポレイテッド 神経変性疾患におけるタンパク質−タンパク質相互作用
AU3474100A (en) 1999-01-25 2000-08-07 Minerva Biotechnologies Corporation Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
US20030083277A1 (en) * 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
GB0100119D0 (en) * 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
US20030027210A1 (en) * 2001-01-03 2003-02-06 Daniel Benjamin Alpha synuclein aggregation assays
US6626963B2 (en) * 2001-09-21 2003-09-30 E. I. Du Pont De Nemours And Company Process for restoring the appearance of pigmented or dyed para-aramid fabric
JP3699046B2 (ja) * 2002-01-09 2005-09-28 株式会社日立メディコ 超音波治療装置
JP4334819B2 (ja) * 2002-05-17 2009-09-30 株式会社日立メディコ 血栓検出装置及び血栓治療装置
WO2003103583A2 (en) 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system

Also Published As

Publication number Publication date
EP1739425A4 (de) 2008-05-21
JPWO2005095958A1 (ja) 2008-02-21
US20090087916A1 (en) 2009-04-02
EP1739425A1 (de) 2007-01-03
WO2005095958A1 (ja) 2005-10-13
EP1739425B1 (de) 2009-09-09
DE602005016537D1 (de) 2009-10-22

Similar Documents

Publication Publication Date Title
DE60320867D1 (de) Verfahren und vorrichtung zur charakterisierung von analyten
ATE442588T1 (de) Testverfahren zur identifizierung eines kandidatenarzneistoffs
DE602006014846D1 (de) Verfahren zur quantifizierung von allergenen
ATE537448T1 (de) Nachweis von rho-proteinen
DE602005021614D1 (de) Gegenionenaustauschverfahren für peptide
NO20011386D0 (no) Nye metoder for fremvisning av (poly)peptider/proteiner pÕ bakteriofage partikler via disulfidbindinger
DE602004022575D1 (de) Verfahren zum selektiven testen von adiponectinmultimeren
ATE441102T1 (de) Verfahren zur detektion von intrazellulären parametern mit lumineszierenden proteinsonden zur selektion von molekülen, die diese parameter ändern kínnen
DE602006006855D1 (de) Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb)
ATE468537T1 (de) Neurodegenerative marker für depression.
BRPI0616712B8 (pt) método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas
ATE528649T1 (de) Verfahren zum nachweis falsch gefalteter proteine und prionen
MX2021011726A (es) Escindasas modificadas, usos de las mismas y kits relacionados.
ATE483981T1 (de) Verfahren, zusammensetzungen und verbindungstests zur hemmung der amyloid-beta-proteinproduktion
ATE548463T1 (de) Lrrk2 polypeptidesubstrate und ihre verwendungen
Domin et al. Neuropeptide Y and its C-terminal fragments acting on Y2 receptor: Raman and SERS spectroscopy studies
ATE397197T1 (de) Verfahren zum erkennen der position von fahrzeugen und system zum erkennen von fahrzeugen in einem geographischen bereich
Ellis‐Steinborner et al. An unusual kynurenine‐containing opioid tetrapeptide from the skin gland secretion of the Australian red tree frog Litoria rubella. Sequence determination by electrospray mass spectrometry
WO2006089801A3 (de) Verfahren zum redox-potential-abhängigen nachweis von targetmolekülen durch wechselwirkende polypeptide
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
ATE455297T1 (de) Mikrosensor zur bestimmung von d-aminosäuren
ATE405827T1 (de) Screening-verfahren
ATE438100T1 (de) Verfahren zum funktionellen nachweis von masps und dessen komplexen
US20110318770A1 (en) Compositions, kits and methods for determining plasmin activity
ATE455305T1 (de) Verfahren zur bestimmung des verhältnisses von zwei verschiedenen peptiden oder polynukleinsäuren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties